Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Other Accumulated Expenses (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Other Accumulated Expenses for 4 consecutive years, with $622000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 76.48% to $622000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $622000.0, a 76.48% decrease, with the full-year FY2024 number at $1.1 million, up 7.25% from a year prior.
  • Other Accumulated Expenses was $622000.0 for Q3 2025 at Mereo BioPharma, down from $777000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.4 million in Q2 2024 to a low of $622000.0 in Q3 2025.
  • A 4-year average of $1.4 million and a median of $1.0 million in 2023 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 24.51% in 2025; the steepest drop was 77.38% in 2025.
  • Mereo BioPharma's Other Accumulated Expenses stood at $1.1 million in 2022, then decreased by 4.67% to $1.0 million in 2023, then grew by 7.25% to $1.1 million in 2024, then crashed by 43.2% to $622000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Other Accumulated Expenses are $622000.0 (Q3 2025), $777000.0 (Q2 2025), and $894000.0 (Q1 2025).